Assessment of Free -β Human Chorionic Gonadotropin for Early Screening of Gestational Diabetes Mellitus

Abstract

Background: Regardless of the level of hyperglycemia, gestational diabetes mellitus is known as any grade of glucose intolerance identified during pregnancy. Factor influencing short and long-term hazards to moms and babies is hyperglycemia.

Aim of the study: to assess free-β human chorionic gonadotropin correlation with gestational diabetes mellitus and its usefulness in predicting gestational diabetes mellitus at 11–14th week of pregnancy.

Material & Methods: The study was prospective, observational cohort study, 80 participants allocated into the gestational diabetes mellitus group (n = 34) and control group (n = 46). Free-β human chorionic gonadotropin were assessed between 11–14 gestational weeks. Screening for using 75-g oral glucose tolerance test following 8-hour overnight fasting, with plasma glucose assessment in fasting and 2 hours at 24-28 weeks' gestation.

Results: There was variance between groups concerning fasting blood glucose & post prandial, where both are elevated in the gestational diabetes mellitus group. A significant difference was observed in the prevalence of a family history of diabetes between the GDM and control groups. The GDM group exhibited a markedly higher proportion of individuals with a family history of diabetes.

 Conclusion: Since there was no variance between the groups under study, using free-β human chorionic gonadotropin as early gestational diabetes mellitus screening test is not suggested.